Overview

Phase I Study in RAD 001 Patients With Relapse AML

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
A phase I clinical study in evaluation of RAD 001 with aracytine and daunorubicine in AML treatment of patients older less than 65 years in relapse
Phase:
Phase 1
Details
Lead Sponsor:
French Innovative Leukemia Organisation
Collaborator:
Novartis Pharmaceuticals
Treatments:
Everolimus
Sirolimus